HLE Glascoat Ltd

- There is no mention of any new capacity expansion or large capital expenditure plans in the near term, indicating no immediate large fundraise through debt or equity. - Maintenance capex is planned but limited (e.g., around EUR 1 million for Thaletec and INR 10-15 crores for India business). - Management indicated plans to reduce overall debt during the ongoing financial year; they aim to keep debt-to-EBITDA below 1.5x. - Annual debt repayment obligations are around INR 35 crores for FY25. - No specific announcement or guidance was given on raising new debt or equity funds at this time. - Focus is on working capital efficiency and debt reduction rather than new fundraising.

- No new production capacity expansion planned in FY25 across all segments, including Thaletec and Indian business. - Routine maintenance capex planned: - Thaletec (Germany): Approx. EUR 1 million maintenance capex. - India business: Around INR 10-15 crores maintenance capex. - CWIP of INR 20 crores relates to civil building and development of R&D center in Anand, with no facility or production capacity enhancement involved. - No capital outlay planned for new projects or capacity increase at this stage. - Acquisition of Kinam has bolstered heat transfer equipment business, expected to continue fostering operational synergies but no new capex indicated. - Focus remains on cost rationalization, operational efficiency, and improving margins rather than expansion capex.

- India business expected to grow between 18% and 20%. - Germany business projected to grow between 10% and 12%. - Overall consolidated revenue guidance given in the range of INR 1,125 to INR 1,150 crores. - Order book has grown over 50% in first two months compared to last year, indicating strong recovery. - Growth driven by specialty chemicals, pharma, and gradually recovering agrochemical sectors. - Thaletec expected to see margin improvement to around 12%. - Kinam revenue expected between INR 180 to 200 crores with EBITDA margins around 25%. - Margins for glass-lined business expected to normalize to 16%-17% in second half of FY25. - Expansion into US market shows positive traction with $11 million order book as of March 2024. - Focus on improving market penetration, value-added product offerings, and sales network expansion.

- The management expects consolidated revenue guidance around INR 1,125 crores to INR 1,150 crores. - India business is targeted to grow between 18% and 20%. - Germany business growth is expected between 10% and 12%. - Margins for India glass lined business to recover gradually, with blended GLE margins between 13%-15%. - Filtration business margins expected around 17%-18% for the financial year. - Thaletec margins expected to be above 10%, with revenue growth prospects. - Kinam segment expected to generate INR 180–200 crores revenue with ~25% EBITDA margins, sustainable going forward. - Management focuses on improving cost efficiency, engineering, and operational productivity, not just cost-cutting. - Debt-to-EBITDA ratio targeted below 1.5, with plans to reduce overall debt. - Revenue growth driven by volume recovery, improved market share, and penetration into new markets. - Margins expected to improve in H2 FY25 as order dispatches materialize.

- As of March 31, 2024, the order book stood at approximately INR 450 crores. - The company is witnessing order book growth in the first two months of the current financial year (FY25), indicating a positive trend. - The management notes a stronger sales network and better market penetration contributing to order inflow. - For the glass lined equipment business specifically, the order book for the first two months of FY25 has grown over 50% compared to the same period last year. - Orders are being booked, not just inquiries, particularly in glass lined equipment, adding to confidence in demand. - The management expects growth in order inflows from sectors like specialty chemicals, pharma, and agrochemical, although agrochemical recovery is slower. - Overall, despite past delays, the company expects revenues and margins to improve in H2 FY25 as these orders get executed.